In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant

Tatsuo Ohira, Yuichiro Ohe, Yuji Heike, Eckhard R. Podack, Kristin J. Olsen, Kazuto Nishio, Makoto Nishio, Yuki Miyahara, Yasunori Funayama, Hayato Ogasawara, Hitoshi Arioka, Hiroshi Kunikane, Minoru Fukuda, Harubumi Kato, Nagahiro Saijo

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

In an attempt to develop the most effective cytokine gene therapy, we transfected mouse interleukin(IL)-2, mouse IL-4, and human IL-6 cDNAs into mouse melanoma cells, B16F10. Transfection with IL-4 cDNA decreased the tumorigenicity of B16F10 most strongly. We investigated whether gene therapy with IL-4-transfected B16F10 cells was possible. Flowcytometric analysis showed that major histocompatibility complex class I and II expression in B16F10 and IL-4-cDNA-transfected B16F10 (B16F10-IL4) cells did not differ. Doubling times of B16F10 and B16F10-IL4 were 20.1 and 21.1 h respectively. The growth of B16F10 cells was retarded if C57BL/6 mice were inoculated with B16F10-IL4 at the contralateral sides. When 5×105 B16F10 cells were transplanted subcutaneously into the flanks of C57BL/6 mice, they all developed a tumor mass, whereas no tumor masses formed in those transplanted with B16F10-IL4 cells within 60 days. No nude, severe combined immunodeficient or beige mice were able to reject parental B16F10 or B16F10-IL4 cells, although, B16F10-IL4 tumor growth in all these immunodeficient mice was slower than that of B16F10. Therefore, we concluded that T and natural killer cells are necessary for rejection of B16F10-IL4 tumor cells.

Original languageEnglish (US)
Pages (from-to)631-635
Number of pages5
JournalJournal of cancer research and clinical oncology
Volume120
Issue number11
DOIs
StatePublished - Nov 1 1994

Keywords

  • B16F10
  • Gene therapy
  • Interleukin-4

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant'. Together they form a unique fingerprint.

  • Cite this

    Ohira, T., Ohe, Y., Heike, Y., Podack, E. R., Olsen, K. J., Nishio, K., Nishio, M., Miyahara, Y., Funayama, Y., Ogasawara, H., Arioka, H., Kunikane, H., Fukuda, M., Kato, H., & Saijo, N. (1994). In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant. Journal of cancer research and clinical oncology, 120(11), 631-635. https://doi.org/10.1007/BF01245372